Avinger Announces Participation in Canaccord Genuity 37th Annual Growth Conference

REDWOOD CITY, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. AVGR, a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Canaccord Genuity 37th Annual Growth Conference in Boston.

Avinger management is scheduled to present on Thursday, August 10, 2017 at 10:30am ET. Interested parties can access the live audio webcast with accompanying slides from the Events section of Avinger's website at www.avinger.com. The webcast replay will be available after the conclusion of the live presentation for 90 days.

About Avinger, Inc.

Founded in 2007, Avinger, Inc. is a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral arterial disease (PAD). Avinger is dedicated to radically changing the way vascular disease is treated through their Lumivascular platform which currently consists of the Lightbox imaging console, the Ocelot family of catheters designed for chronic total occlusions (CTOs), and Pantheris designed for atherectomy.  Avinger is based in Redwood City, CA.  For more information, please visit www.avinger.com.

Investor Contact:
Matt Ferguson
Avinger, Inc.
(650) 241-7917
ir@avinger.com